Dx at heart of high-profile NHS drug approval
This article was originally published in Clinica
It is extremely rare that a high-profile approval of a pharmaceutical for NHS use is as dependent on diagnostic testing and monitoring as that of Herceptin, as recommended today by the National Institute for Health and Clinical Excellence (NICE). According to the draft guidance, the use of trastuzumab for early HER2-positive breast cancer will be subject to tight cardiac function parameters that are to be assessed prior to treatment, and then every three months.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.